Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-03-21
2006-03-21
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S018000, C435S338000, C530S388260
Reexamination Certificate
active
07015008
ABSTRACT:
The present invention features antibodies referred to herein as “MAb50-4” and “MAb184-10”, and polypeptides that compete with MAb50-4 and MAb184-10 for binding to CYP2D6. MAb50-4 can be produced by ATCC No. PTA-3489, while MAb184-10 can be produced by ATCC No. PTA-1999.
REFERENCES:
patent: 5693762 (1997-12-01), Queen et al.
patent: 5830667 (1998-11-01), Alvarez et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6056957 (2000-05-01), Chou et al.
patent: 6060253 (2000-05-01), Gelboin et al.
patent: 6060353 (2000-05-01), Koh et al.
patent: WO 95/17516 (1995-06-01), None
patent: WO 00/04861 (2000-02-01), None
patent: WO 00/04864 (2000-02-01), None
Coon, M. et al. “Cytochrome P450: progress and predictions”, FASEB, 1992, vol. 6, pp. 669-673.
Gelboin, H. et al. “A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism”, Pharmacogenetics, 1997, vol. 7, pp. 469-477.
Gelboin, H. et al. “Inhibitory and Noninhibitory Monoclonal Antibodies to Human Cytochrome P450 2E1”, Chem. Res. Toxicol., 1996, vol. 9, pp. 1023-1030.
Gelboin, H. et al. “Inhibitory and Noninhibitory Monoclonal Antibodies to Human Cytochrome P450 3A3/4”, Biochemical Pharmacology, 1995, vol. 50, pp. 1841-1850.
Gonzalez, F. “The Molecular Biology of Cytochrome P450s”, Pharmacological Reviews, 1989, vol. 40, pp. 243-288.
Guengerich, F. et al. “Cytochrome P-450 Oxidations and the Generation of Biologically Reactive Intermediates”, Advances in Experimental Medicine and Biology, 1991, vol. 283, pp. 1-11.
Guengerich, F. “Metabolic Activation of Carcinogens”, Pharmac. Ther., 1992, vol. 54, pp. 17-61.
Krausz, K. et al. “Inhibitory Monoclonal Antibodies to Human Cytochrome P450 2D6”, Biochemical Pharmacology, 1997, vol. 54, pp. 15-17.
Mei, Q. et al. “Role of a Potent Inhibitory Monoclonal Antibody to Cytochrome P-450 3A4 in Assessment of Human Drug Metabolism”, The Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 291, pp. 749-759.
Nelson, D. et al. “P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature”, Pharmacogenetics, 1996, vol. 6, pp. 1-42.
Ngui, J. et al. “Cytochrome P450 3A4-Mediated Interaction of Diclofenac and Quinidine”, Drug Metabolism and Disposition, 2000, vol. 28, pp. 1043-1050.
Shou, M. et al. “Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivaties: enzyme specificity, interindividual distribution and metabolic contribution in human liver”, Pharmacogenetics, 1998, vol. 8, pp. 391-401.
Shou, M. et al. “Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone”, Carcinogenesis, 1997, vol. 18, pp. 207-214.
Shou, M. et al. “Sigmoidal kinetic model for two co-operative substrate- binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives”, Biochem J., 1999, vol. 340, pp. 845-853.
Shou, M. et al. “Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism”, European Journal of Pharmacology, 2000, vol. 394, pp. 199-209.
Tang, C. et al. “Major Role of Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) in the Oxidative Metabolism of Celecoxib, Novel Cyclooxgenase-II Inhibitor”, The Journal of Pharmacology and Experimental Therapeutics, 2000, vol. 293, p. 453-459.
Tang, C. et al. “Substrate-Dependent Effect of Acetonitrile on Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) Activity”, Drug Metabolism and Disposition, 2000, vol. 28, pp. 567-572.
Yang, T. et al. “Inhibitory Monoclonal Antibody to Human Cytochrome P450 2B6”, Biochemical Pharmacology, 1998, vol. 55, pp. 1633-1640.
Shou, M. et al. “Two Inhibitory Monoclonal Antibodies Against Human CYP2D6”, Drug Metabolism Reviews, 2000, vol. 32, p 211, abstract No. 149.
Gelboin, H. et al. “Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery”, Trends in Pharmacological Sciences, 1999, vol. 20, pp. 432-438.
Klein, R. et al. “Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes”, Clinical and Experimental Immunology, 1999, vol. 118, pp. 290-297.
Engel, G. et al. “Prediction of CYP2D6-mediated polymorphic drug metablolism (sparteine type) based on in virto investigations”, Journal of Chromatography, 1996, vol. 678, pp. 93-103.
Mei Qin
Shou Magang
Heber Sheldon O.
Merck & Co. , Inc.
Saunders David
Tribble Jack L.
LandOfFree
Antibodies for human cytochrome P450 2D6 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies for human cytochrome P450 2D6, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies for human cytochrome P450 2D6 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3549371